Severe Relapse After Cessation of Immunosuppressive Therapy in a Patient With Neuromyelitis Optica Spectrum Disorder

被引:3
|
作者
Hyun, Jae-Won [1 ]
Kim, Gayoung
Kim, Yeseul [1 ]
Jeong, In Hye [1 ]
Kim, Su-Hyun [1 ]
Kim, Ho Jin [1 ]
机构
[1] Natl Canc Ctr, Dept Neurol, Res Inst & Hosp, 323 Ilsan Ro, Goyang, South Korea
关键词
neuromyelitis optica spectrum disorder; immunosuppressive therapy; relapse;
D O I
10.1097/NRL.0000000000000095
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The optimal duration of immunosuppressive therapy (IT) for neuromyelitis optica spectrum disorder (NMOSD) has not been established. Here, we report a case of severe relapse after early cessation of IT. Case Report: A 32-year-old woman presented with a 2-week history of intractable vomiting and hiccups followed by quadriplegia with respiratory insufficiency. Spinal cord MRI showed longitudinally extensive transverse myelitis (LETM) and aquaporin-4-immunoglobulin-G (AQP4-IgG) was positive. She was diagnosed with NMOSD and IT was initiated. She did not experience any clinical attacks during 42 months of IT and her AQP4-IgG status was negative. IT was discontinued on her own decision; 36 months later, the patient experienced a severe LETM relapse with paraplegia, and her AQP4-IgG status reverted to positive. Conclusion: This case suggests that clinicians should exercise caution before discontinuing effective IT in patients with NMOSD.
引用
收藏
页码:97 / 98
页数:2
相关论文
共 50 条
  • [21] Neuromyelitis optica spectrum disorder in a patient with myasthenia gravis
    Caetano, A.
    Pinto, M.
    Mendonca, M.
    Aleixo Correia, A. S.
    Pelejao, M. R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 697 - 697
  • [22] Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient
    Pestchanker, Claudia
    Diaconchuk, Melina
    Lopez, Paula
    Rosa Montano, Maria
    Romero, William
    Zalazar, Guillermo
    Carnero Contentti, Edgar
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (01) : 150 - 153
  • [23] Factors associated with disease relapse rate in the Neuromyelitis optica spectrum disorder
    Li, Hai-yun
    Cui, Cai-san
    Yang, Hui-min
    Jiang, Wen-jing
    Yang, Xiang-dong
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2024, 134 (10) : 1114 - 1119
  • [24] Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder
    Tahara, Masayuki
    Oeda, Tomoko
    Sawada, Hideyuki
    LANCET NEUROLOGY, 2020, 19 (07): : 564 - 564
  • [25] Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder
    Sechi, Elia
    Parks, Natalie E.
    Koeller, Kelly K.
    Flanagan, Eoin P.
    NEUROLOGY, 2019, 92 (07) : 343 - 344
  • [26] Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report
    Chatterton, Sophie
    Parratt, John Douglas Edward
    Ng, Karl
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [27] Disease outcomes in the absence of a relapse in patients with neuromyelitis optica spectrum disorder
    Royston, M.
    Kielhorn, A.
    Tanvir, I.
    Sabatella, G.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 151 - 151
  • [28] Statistical evaluation of cluster formation of relapse in neuromyelitis optica spectrum disorder
    Akaishi, Tetsuya
    Nakashima, Ichiro
    NEURAL REGENERATION RESEARCH, 2024, 19 (09) : 1888 - 1889
  • [29] Statistical evaluation of cluster formation of relapse in neuromyelitis optica spectrum disorder
    Tetsuya Akaishi
    Ichiro Nakashima
    Neural Regeneration Research, 2024, 19 (09) : 1888 - 1889
  • [30] Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Lucchinetti, Claudia F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (07): : 631 - 639